Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Tlr7/8 receptor antagonists: MerckRecent Research Landscape

Uncontrolled innate immune signaling triggers chronic inflammatory disorders, which these molecular structures mitigate through selective receptor antagonism. Precise modulation of the TLR pathway prevents systemic toxicity while maintaining therapeutic efficacy.

What technical problems is Merck addressing in Tlr7/8 receptor antagonists?

Excessive neuroinflammatory tissue damage

(5)evidences

Uncontrolled immune responses following acute cerebrovascular events lead to secondary neuronal death. Reducing this inflammatory cascade prevents permanent neurological deficit.

Pathological innate immune overactivation

(4)evidences

Uncontrolled signaling through TLR7/8 pathways leads to chronic inflammation and autoimmune tissue damage. Inhibiting these receptors prevents pathological immune responses in systemic disorders.